Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

NCT ID: NCT03525119

Last Updated: 2022-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 900 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-16
• Study Completion Date: 2019-07-09

Brief Summary

The purpose of this study is to investigate the immunogenicity and safety of the concomitant administration of TDV (subcutaneous [SC] injection) and of hepatitis A virus (HAV) vaccine (intramuscular [IM] injection) in healthy participants aged 18 to 60 years living in country(ies) non-endemic for both dengue and hepatitis.

Detailed Description

The vaccine tested in this study is TDV. TDV co-administered with HAV vaccine will be tested to assess immunogenicity and safety in healthy participants in non-endemic area(s) for dengue and HAV.

The study will enroll approximately 900 patients. Participants will be randomly assigned to one of the three groups-which will remain undisclosed to the observer. Participants will be randomized in 1:1:1 ratio to receive:

• Group 1: HAV vaccine (IM) and TDV placebo-matching injection (SC), co-administered at Day 1 (Month 0 [M0]); TDV placebo-matching injection (SC) administered at Day 90 (Month 3 [M3])
• Group 2: TDV (SC) and HAV placebo-matching injection (IM), co-administered at Day 1 (Month 0 [M0]); TDV (SC) administered at Day 90(Month 3 [M3])
• Group 3: TDV (SC) and HAV vaccine (IM), co-administered at Day 1 (Month 0 [M0]); TDV (SC) administered at Day 90 (Month 3 [M3])

This multi-center trial will be conducted in United Kingdom. The overall time to participate in this study is 270 days. Participants will have multiple visits to the clinic with a 6-months follow up after the last study administration, including a final visit at Day 270.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

HAV Vaccine 1.0 ml + Placebo/ Placebo

HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).

Group Type: OTHER

HAV Vaccine

Intervention Type: BIOLOGICAL

HAV Vaccine IM injection.

TDV Placebo

Intervention Type: BIOLOGICAL

Placebo-matching (normal saline (0.9% NaCl) SC injection.

TDV 0.5 ml + Placebo/ TDV 0.5 ml

TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).

Group Type: EXPERIMENTAL

TDV

Intervention Type: BIOLOGICAL

TDV SC injection

HAV Vaccine Placebo

Intervention Type: BIOLOGICAL

Placebo-matching (normal saline (0.9% NaCl) IM injection.

TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml

TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).

Group Type: EXPERIMENTAL

TDV

Intervention Type: BIOLOGICAL

TDV SC injection

HAV Vaccine

Intervention Type: BIOLOGICAL

HAV Vaccine IM injection.

Interventions

TDV

TDV SC injection

Intervention Type: BIOLOGICAL

HAV Vaccine

HAV Vaccine IM injection.

Intervention Type: BIOLOGICAL

TDV Placebo

Placebo-matching (normal saline (0.9% NaCl) SC injection.

Intervention Type: BIOLOGICAL

HAV Vaccine Placebo

Placebo-matching (normal saline (0.9% NaCl) IM injection.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. The participant is aged 18 to 60 years, inclusive.

2. Participants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and the clinical judgment of the Investigator.

3. The participant signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.

4. Participants who can comply with trial procedures and are available for the duration of follow-up.

Exclusion Criteria

1. Participants with an elevated oral temperature (≥38°C or 100.4°F) within 3 days of the intended date of vaccination.

2. Known hypersensitivity or allergy to any of the vaccine components (including excipients of the investigational vaccines or placebo).

3. Participants with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the trial.

4. Participants with any history of progressive or severe neurologic disorder, seizure disorder orneuro-inflammatory disease (eg, Guillain-Barré syndrome).

5. Participants with history or any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose additional risk to the participant due to participation in the trial.

6. Known or suspected impairment/alteration of immune function, including:

1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed).

2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥ 2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0).

3. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (Month 0) or planned administration during the trial.

4. Receipt of immunostimulants within 60 days prior to Day 1 (Month 0).

5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0).

6. Human immunodeficiency virus (HIV) infection or HIV-related disease.

7. Hepatitis A virus (HAV) infection.

8. Hepatitis C virus infection.

9. Genetic immunodeficiency.

7. Abnormalities of splenic or thymic function.

8. Participants with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

9. Participants with any serious chronic or progressive disease according to judgment of the Investigator (eg, neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).

10. Participants with body mass index (BMI) greater than or equal to 35 kg/m^2 (=weight in kg/[height in meters^2]).

11. Participants participating in any clinical trial with another investigational product 30 days prior to Day 1 (Month 0) or intent to participate in another clinical trial at any time during the conduct of this trial.

12. Participants who received any other vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial or who are planning to receive any vaccine within 28 days of trial vaccine administration.

13. Previous HAV vaccination (in a clinical trial or with an approved product).

14. Participants involved in the trial conduct or their first degree relatives.

15. Participants with history of substance or alcohol abuse within the past 2 years.

16. Female participants who are pregnant or breastfeeding.

17. Females of childbearing potential who are sexually active, and who have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1 (Month 0).

1. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: bilateral tubal ligation (at least 1 year previously), bilateral oophorectomy (at least 1 year previously) or hysterectomy

2. Acceptable birth control methods are defined as one or more of the following:

i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring).

ii. Barrier method (condom with spermicide or diaphragm with spermicide) each and every time during intercourse.

iii. Intrauterine device (IUD). iv. Monogamous relationship with vasectomized partner (partner must have been vasectomized for at least 6 months prior to Day 1 [Month 0]).

Other contraceptive methods may be considered in agreement with the Sponsor and implemented only after approval of a substantial amendment by the regulatory authorities and by the appropriate ethics committee.

18. Females of childbearing potential who are sexually active, and who refuse to use an acceptable contraceptive method up to 6 weeks after the last dose of trial vaccine (Day 90 [M3]). In addition, they must be advised not to donate ova during this period.

19. Any positive or indeterminate pregnancy test.

20. Previous and planned vaccination (during the trial conduct) against any flaviviruses including dengue, yellow fever (YF), Japanese Encephalitis (JE) viruses or tick-borne encephalitis.

21. Previous participation in any clinical trial of a dengue or other flavivirus (eg, West Nile [WN] virus) candidate vaccine, except for participants who received placebo in those trials.

22. Participants with a current or previous infection with a flavivirus such as dengue, Zika, YF, JE, WN fever, tick-borne encephalitis or Murray Valley encephalitis and participants with a history of prolonged (≥1 year) habitation in a dengue endemic area.

23. Participants with contraindications, warnings and/or precautions to vaccination with the HAV vaccine as specified within the product information.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Synexus - Midlands

Edgbaston, Birmingham, United Kingdom

Synexus - Lancashire

Chorley, Lancashire, United Kingdom

Synexus - Merseyside

Waterloo, Liverpool, United Kingdom

Royal Hallamshire Hospital

Sheffield, Yorkshire, United Kingdom

Synexus - Wales

Cardiff, , United Kingdom

Synexus - Scotland

Glasgow, , United Kingdom

North East Clinical Research Centre, Hexham General Hospital

Hexham, , United Kingdom

Synexus - Manchester

Manchester, , United Kingdom

Synexus - Thames Valley

Reading, , United Kingdom

North Tees Clinical Research Centre, Middlefield Centre, University Hospital of North Tees

Stockton-on-Tees, , United Kingdom

Countries

United Kingdom

References

Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, Mandaric S, Rauscher M, Brose M, Lefevre I, Folschweiller N, Wallace D. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine. 2023 Feb 10;41(7):1398-1407. doi: 10.1016/j.vaccine.2023.01.007. Epub 2023 Jan 19.

Reference Type: DERIVED

PMID: 36681529 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://clinicaltrials.takeda.com/study-detail/5f6b60224db2bf003ab4969e?idFilter=%5B%22DEN-314%22%5D

To obtain more information about this study, click this link.

Other Identifiers

2017-001071-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1192-7761

Identifier Type: OTHER

Identifier Source: secondary_id

18/NW/0008

Identifier Type: REGISTRY

Identifier Source: secondary_id

DEN-314

Identifier Type: -

Identifier Source: org_study_id